Your GLP-1 Not Working? What to Check and Do Next

Decorative hand-drawn title card illustration

If your GLP-1 medication seems to have stopped working, the most likely explanation is a plateau or incomplete optimization, not absolute treatment failure. True nonresponse, defined clinically as losing less than 5% of your starting body weight after a full, supervised titration, affects roughly 10–15% of patients in major trials. For everyone else, the culprit is usually one of several fixable factors: a subtherapeutic dose, behavioral drift, an unaddressed medical condition, or a medication interaction.

Before your next clinician visit, run through this checklist:

Confirm your dose and adherence. Are you injecting on schedule, at the correct site, with medication stored properly in the refrigerator?
Check titration status. Have you reached the full therapeutic dose, or are you still on a starter dose?
Track appetite changes. Even if the scale is flat, reduced hunger is a sign the drug is active.
Review recent medication changes. Antidepressants, antipsychotics, or corticosteroids started around the time of your stall are worth flagging.
Assess key lifestyle gaps. Low protein intake, no resistance training, and poor sleep each independently blunt weight loss.
Gather recent labs. TSH, A1c, and a basic metabolic panel give your clinician a faster path to answers.

Pro Tip: Before concluding your medication is not working, measure non-scale victories: waist circumference, hunger cues, energy levels, and how your clothes fit. These often tell a clearer story than the scale alone, especially in the first 12 weeks.

Key Takeaways

Most GLP-1 plateaus are fixable with targeted troubleshooting across dose, diet, sleep, and medical screening, and true nonresponse affects a minority of patients.

Point	Details
Clinical response threshold	Losing ≥5% of starting body weight is the standard definition of meaningful weight loss on GLP-1 therapy.
Nonresponder prevalence	Roughly 10–15% of patients in major trials fail to reach the 5% threshold after optimized therapy.
First steps to take	Confirm adherence, titration status, protein intake, sleep quality, and screen for weight-promoting medications.
Reassessment window	Evaluate early response at 12–16 weeks; conduct a full assessment at 6 months before switching agents.
Glpcare’s role	Glpcare combines clinician supervision, nutrition coaching, and wearable biometrics to identify and address plateau drivers faster.

What does “GLP-1 not working” actually mean?
Common reasons your GLP-1 therapy may appear ineffective
What your clinician will review when progress stalls
Lifestyle changes that improve your results on GLP-1 therapy
Medical escalation options when lifestyle changes are not enough
What the latest research says about GLP-1 resistance
Glpcare addresses the gaps that cause most GLP-1 plateaus
Sources
FAQ

What does “GLP-1 not working” actually mean?

The phrase covers three distinct situations, and your clinician needs to know which one applies before making any change.

A plateau is the most common scenario. You lost weight early, then progress slowed or stopped. This is a normal physiologic response: as your body gets lighter, it burns fewer calories at rest, and the appetite-suppressing effect of the drug may feel less dramatic. A plateau does not mean the medication stopped working.

Tolerance refers to a gradual reduction in the drug’s appetite-suppressing effect over time, even at the same dose. Some patients notice hunger returning weeks or months into therapy. This is different from nonresponse and often responds to dose adjustment.

Yale Medicine notes that clinicians use the 5% threshold as the clinical definition of meaningful weight loss, and that losing even this amount is associated with measurable health benefits, including improved blood pressure and glycemic control.

Reassessment timelines to know:

Early response signal: weight loss typically begins within the first few weeks of reaching a therapeutic dose.
First checkpoint: 12–16 weeks at or near the target dose is a reasonable window to assess early response.
Full evaluation: 6 months of optimized therapy is the standard window before a clinician considers switching agents or escalating care.

For a week-by-week picture of what a normal response curve looks like, GLPCare’s evidence guide walks through expected milestones and when slower progress is still within range.

Common reasons your GLP-1 therapy may appear ineffective

Most cases of semaglutide not losing weight trace back to one or more of these eight categories. Read through them honestly before your next appointment.

Missed or inconsistent dosing. GLP-1 receptor agonists require consistent weekly administration to maintain steady plasma levels. A missed dose here and there compounds over time.
Incomplete titration. Many patients plateau on a starter dose and never reach the full therapeutic dose. Semaglutide’s maintenance dose for weight loss is 2.4 mg weekly; tirzepatide’s is up to 15 mg. If you are on 0.5 mg or 5 mg, you may simply need more time and a higher dose.
Concomitant medications. Certain antidepressants (mirtazapine, paroxetine), antipsychotics (olanzapine, quetiapine), insulin, and corticosteroids promote weight gain or counteract the drug’s effect. WebMD’s clinical review notes that people with type 2 diabetes on insulin tend to lose less weight on GLP-1 therapy than those without diabetes.
Unaddressed medical conditions. Hypothyroidism, Cushing’s syndrome, and untreated obstructive sleep apnea each independently drive weight gain or block loss. None of these will resolve with a higher GLP-1 dose alone.
Behavioral drift. Verywell Health identifies low protein intake, loss of resistance training, liquid calories, and reward eating as common, remediable contributors to a weight loss stall on GLP-1. The drug reduces appetite, but it does not restructure eating habits automatically.
Compounded or low-quality formulations. FDA-approved semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have standardized dosing and bioavailability. Some compounded products use semaglutide sodium or acetate salts that lack equivalent clinical evidence. If you are using a compounded product and not seeing results, the formulation itself may be a variable.
Metabolic adaptation. As you lose weight, your resting metabolic rate drops. This is normal physiology, not a sign the drug has failed. Structured resistance training is the most reliable way to slow this adaptation.
Genetic and biological factors. A minority of patients have biological characteristics that reduce their response to GLP-1 receptor agonists. Research into this area is growing, covered in detail in the genetics section below.

What your clinician will review when progress stalls

A good clinician does not simply increase the dose when weight loss stalls. They work through a structured review. Knowing what to expect helps you prepare and speeds up the process.

Clinician review area	What to bring or discuss	What they may find or change
Adherence and technique	Injection log, storage method, site rotation	Missed doses, improper storage, or injection errors
Titration history	Dose history and tolerability notes	Subtherapeutic dose; may increase to maximum tolerated dose
Concomitant medications	Full medication list including supplements	Weight-promoting drugs; possible substitutions or timing changes
Labs	TSH, A1c, fasting glucose, basic metabolic panel, cortisol if indicated	Hypothyroidism, insulin resistance, adrenal issues
Sleep and mood	Sleep quality, snoring history, mood changes	Obstructive sleep apnea, depression, or anxiety affecting appetite
Body composition	Waist circumference, clothing fit, strength changes	Muscle loss masking fat loss on the scale

Hands preparing GLP-1 injection at home

Mayo Clinic recommends TSH, A1c, and a medication review as first-line investigations when weight loss stalls on any pharmacotherapy. Houston Methodist adds that clinicians differentiate a plateau from nonresponse by examining appetite control and lifestyle factors before concluding the medication is ineffective.

Pro Tip: Bring a one-page summary to your appointment: your starting weight, current weight, dose history, any appetite changes, and your current sleep and exercise habits. Clinicians who have this data in front of them spend less time gathering history and more time problem-solving.

Lifestyle changes that improve your results on GLP-1 therapy

Medication does the heavy lifting on appetite, but these four habits determine how much of the weight you lose is fat versus muscle, and whether the plateau breaks.

Prioritize protein at every meal. Aim for at least 1.2–1.6 g of protein per kilogram of body weight daily. Protein preserves lean mass during caloric restriction and keeps you fuller longer. Use Glpcare’s protein calculator to convert this into a daily gram target based on your weight.
Add progressive resistance training. Two to three sessions per week of compound movements (squats, rows, presses) stimulate muscle protein synthesis and counteract the metabolic slowdown that accompanies weight loss. If you are new to strength training, a single session with a certified personal trainer to build a basic program is worth the investment. For detailed guidance on preserving muscle while on GLP-1s, see Glpcare’s guide on preventing muscle loss.
Protect your sleep. Poor sleep raises ghrelin (the hunger hormone) and lowers leptin (the satiety hormone), directly counteracting the drug’s appetite suppression. Seven to nine hours of consistent sleep is not optional when you are trying to lose weight on a GLP-1.
Cut liquid calories and track hunger cues. GLP-1s slow gastric emptying and reduce appetite, but they do not block the caloric impact of sweetened beverages, alcohol, or high-calorie smoothies. Use the drug’s appetite suppression as a cue to eat less, not as permission to drink more.
Track objective metrics beyond the scale. Waist circumference, clothing fit, energy during workouts, and sleep quality are all meaningful signals. Glpcare’s GLP-1 tracker guide explains how to build a simple weekly tracking habit that gives your clinician better data.

Pro Tip: Run a protein-anchored food log for two to four weeks. If you find you are averaging under 80 g of protein per day, behavioral drift is almost certainly contributing to your plateau, and fixing it costs nothing.

Medical escalation options when lifestyle changes are not enough

Dose increase to maximum tolerated dose. Before switching agents, confirm you have reached the highest dose you can tolerate. Many patients are undertitrated. This step alone resolves a significant portion of apparent nonresponse cases.
Switching agents. Tirzepatide (a dual GIP/GLP-1 agonist) produces greater average weight loss than semaglutide in head-to-head trials, and some patients who respond poorly to one agent respond better to another. Cross-trial comparisons have limitations, but a switch is a reasonable clinical option when one agent fails after full titration.
Adding non-GLP agents. Under clinician supervision, adding a medication from a different class (such as a topiramate-containing combination or bupropion/naltrexone) may address appetite pathways that GLP-1s do not fully target. This is a specialist-level decision.
Referral to an obesity medicine specialist. If your primary care provider has exhausted first-line options, a board-certified obesity medicine physician can conduct a more thorough phenotypic assessment and consider combination strategies or clinical trial enrollment.
Bariatric surgery evaluation. For patients with a BMI of 35 or above with comorbidities, or 40 and above without, bariatric surgery remains one of the most effective long-term interventions. A referral for surgical evaluation does not commit you to surgery; it opens the conversation.
Cost and coverage planning. GLP-1 medications are expensive, and insurance coverage varies widely. Glpcare’s insurance coverage guide outlines what to ask your insurer and how to document medical necessity. Weigh the cost of continued therapy against the likelihood of benefit, especially if you have not reached the 5% threshold after a full trial.

Stopping GLP-1 therapy without a long-term plan carries its own risk: research published in PubMed Central shows that discontinuation commonly leads to substantial weight regain, which means any escalation decision should include a maintenance strategy.

Yale Medicine estimates that roughly 10–15% of patients fail to reach the 5% threshold even after optimized therapy. If you are in that group, the cost of continuing a medication with low likelihood of benefit is a legitimate clinical and financial consideration.

What the latest research says about GLP-1 resistance

The science of why some people respond poorly to GLP-1 drugs is moving quickly, and the findings are clinically relevant even if they are not yet standard of care.

PAM gene variants. Stanford Medicine researchers identified variants in the PAM gene, carried by roughly 10% of the population, that appear to reduce GLP-1 biological activity. In analyses of diabetes trials, carriers showed reduced drug responsiveness. The mechanism involves PAM’s role in processing peptide hormones, including GLP-1 itself.
GLP1R and GIPR signals. Genetic studies have also flagged variants in the GLP-1 receptor gene (GLP1R) and the GIP receptor gene (GIPR) as potential contributors to variable response. These findings help explain why some patients respond well to semaglutide but better to tirzepatide, which targets both receptors.
Phenotype research. Scientific American summarizes research proposing that obesity is biologically heterogeneous. The “hungry brain” phenotype, driven by reward-based eating and central appetite dysregulation, may respond differently to GLP-1s than the “hungry gut” phenotype, which is driven by rapid gastric emptying and postprandial hunger. Matching the drug mechanism to the phenotype is an active area of investigation.
What this means for you today. Genetic testing for GLP-1 resistance is not yet a routine clinical test. It is not something your clinician can order at a standard lab and use to guide prescribing. If you are interested, ask whether any research programs in your area are studying pharmacogenomics for obesity treatment. For now, the practical implication is that nonresponse is not a personal failing; it may have a biological basis that current tools cannot yet fully characterize.

What the data really tells us about “failure” on GLP-1 therapy

The word “failure” does not belong in this conversation. A clinician who uses it is applying the wrong frame.

What the data actually shows is variability. Scientific American’s review reports that nonresponder proportions vary across datasets and definitions, sometimes reaching higher than 15% in certain trial subgroups. That variability is not random. It reflects real biological differences in how people process GLP-1 signals, combined with environmental and behavioral factors that are often modifiable.

The most productive clinical approach is iterative and data-driven. Bring your medication log, your food patterns, your sleep data, and your recent labs to every appointment. Ask your clinician for a time-limited plan, specifically a 12–16 week window with defined metrics, before making any major change. That structure protects you from both premature discontinuation and from staying on a therapy that genuinely is not working.

Clinicians at Yale Medicine emphasize that even a 5% loss carries measurable health benefits, and that patient expectations frequently exceed clinical targets. Closing that gap with honest, shared decision-making is what good obesity medicine looks like.

Glpcare addresses the gaps that cause most GLP-1 plateaus

Most plateaus come down to the same handful of gaps: undertitration, low protein intake, no objective sleep or activity data, and infrequent clinician contact. Glpcare’s integrated program is built to close all of them in one place.

Glpcare

The Glpcare system pairs prescription GLP-1 medication (semaglutide or tirzepatide, shipped to your door) with personalized nutrition coaching, a proprietary wearable band that tracks sleep, heart rate, and activity with medical-grade sensors, and an AI-driven app that logs your dose and generates custom health insights between visits. Licensed clinicians review your biometric data and adjust your plan based on what the numbers actually show, not just what you remember from your last appointment. When escalation is needed, the same clinical team coordinates the next step.

If your scale has not moved in weeks, the GLP-1 readiness quiz takes five minutes and gives you a clearer picture of where your program stands and what to address first. You can also use the protein intake calculator to set a daily target today, before your next clinical visit. For objective tracking of sleep and activity, the GLP Care Band gives your clinician the data they need to troubleshoot faster.

Close-up of fitness band tracking health metrics

Sources

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

Why am I not losing weight on my GLP-1 medication?

The most common reasons are incomplete titration to the full therapeutic dose, behavioral drift (low protein, no resistance training), an unaddressed medical condition like hypothyroidism, or a weight-promoting medication taken alongside the GLP-1. A clinician review of your dose history, labs, and lifestyle habits usually identifies the cause.

Why do some people not respond to GLP-1 drugs at all?

Biological phenotype differences in how appetite is regulated also contribute to variable response.

What can you do if your GLP-1 is not working?

Confirm you have reached the maximum tolerated dose, optimize protein intake and resistance training, screen for medical causes, and bring your labs and medication log to your clinician. If progress is still absent after 6 months of optimized therapy, discuss switching agents, adding a complementary medication, or referral to an obesity medicine specialist.

Why is my GLP-1 not suppressing my appetite anymore?

Reduced appetite suppression over time can reflect tolerance at the current dose, behavioral adaptation, or inadequate sleep raising hunger hormones. A dose adjustment or a structured review of sleep and eating patterns with your clinician is the appropriate first step, not discontinuation.

Your GLP-1 Not Working? What to Check and Do Next